<DOC>
	<DOC>NCT00268710</DOC>
	<brief_summary>Primary objectives: - To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting. Secondary objectives: - To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as second line therapy in HRPC - To evaluate PSA response (PSA: Prostate Specific Antigen) - To evaluate symptomatic response - To evaluate Quality of life - To evaluate patient safety of weekly versus q3 weekly regimens of Taxotere®.</brief_summary>
	<brief_title>Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically/cytologically proven prostate adenocarcinoma Progression or non response with previous chemotherapy regimen (excluding Taxotere®) Received previous mitoxantrone/prednisone or one other chemotherapy regimen including emcyt +/ vinblastine Castration levels of testosterone (&lt;50 ng/dL ) ECOG performance status 02 Laboratory requirements : 1. Hematology: Neutrophils ≥ 1.5 x 10^9/L Hemoglobin &gt; 10 g/dL (prior transfusion permitted). Platelets ≥ 100 x 10^9/L 2. Hepatic function: Total bilirubin &lt; the uppernormal limit of the institution. ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the uppernormal limit of the institution. 3. Renal function: Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1) No severe or uncontrolled disease Exclusion Criteria Chemotherapy within the last 4 weeks Antiandrogen therapy within the last 4 weeks. Prior malignancy except the following: adequately treated nonmelanomatous skin cancer and superficial bladder cancer from which the patient has been diseasefree for &gt;2 years. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening. Treatment with any other anticancer therapy (except LHRH agonists) including any prescribed compounds and/or OTC products for the treatment of prostate cancer must be stopped prior to study entry. Other serious illness, psychiatric or medical condition that would not permit the patient to be managed according to the protocol including active uncontrolled infection and significant cardiac dysfunction.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>